Renalytix AI PLC KidneyIntelX study accepted for publication
July 01 2020 - 1:00AM
RNS Non-Regulatory
TIDMRENX
Renalytix AI PLC
01 July 2020
Renalytix AI plc
("RenalytixAI", the "Company")
KidneyIntelX validation study accepted for publication in
American Society of Nephrology Journal Kidney360
NEW YORK, July 1, 2020 - Renalytix AI plc ( LSE: RENX), an
artificial intelligence -enabled in vitro diagnostics company
focused on optimizing clinical management of kidney disease to
drive improved patient outcomes and lower healthcare costs ,
announces results of a clinical validation study have undergone
peer-review and have been accepted for publication in the American
Society of Nephrology Journal, Kidney360.
Highlights:
-- KidneyIntelX identifies patients at the highest risk of
progressive kidney function decline in two distinct cohorts and
clinical settings with more accuracy than existing methods
-- The KidneyIntelX(TM) algorithm accurately predicted rapid
kidney function decline (RKFD) and/or 40% sustained decline in
kidney function, or kidney failure in patients with Type 2 diabetes
and of African Ancestry with high-risk APOL1 genotypes
-- The positive predictive value (PPV) of KidneyIntelX(TM) for
progressive kidney function both patient groups exceeded 60% and
the negative predictive value exceeded 90%
The published manuscript titled "Validation of a
machine-learning-derived prognostic test (KidneyIntelX) integrating
biomarkers and EHR data to predict longitudinal-kidney outcomes" is
available through the Early Access format of the American Society
of Nephrology journal, Kidney360:
https://kidney360.asnjournals.org/content/early/2020/06/29/KID.0002252020
The study provides details of the primary analysis and numerous
sub-analyses which demonstrate robust performance of the
KidneyIntelX test in the two clinical contexts. These validation
results complement the multi-center validation study in patients
with prevalent diabetic kidney disease previously reported (
https://www.medrxiv.org/content/10.1101/2020.06.01.20119552v3 ).
These findings were reported in part previously in BioXriv, the
preprint server for biology, operated by Coldspring Harbor
Laboratory (bioRxiv 587774; doi: https://doi.org/10.1101/587774
),
The primary objective of this validation study was to
demonstrate if the KidneyIntelX artificial intelligence-enabled
algorithm was able to predict which patients are at highest risk of
adverse kidney outcomes with more accuracy than the existing
standard of care. The optimised KidneyIntelX assay, combining
sTNFR1, sTNFR2 and KIM-1 together with clinical data from
electronic health records, achieved a PPV of 62%in the top 15%
highest risk of the T2D population vs. 46% as classified by the
clinical model (p<0.01 for comparison). Likewise, in the
Apolipoprotein L1 high-risk ( APOL1 ) genotype cohort, the PPV of
KidneyIntelX was 62% in the top 15% highest risk of APOL1-HR
population vs. PPV of 39%, as classified by the clinical model,
(p<0.01 for comparison). The study included 871 patients with
Type 2 diabetes and 498 patients of African Ancestry with APOL1
high-risk genotypes (i.e., one copy of the genetic risk variant on
both chromosomes).
Better risk stratification tools are needed to facilitate the
application of novel treatments for DKD and CKD in patients with
relatively preserved kidney function. Earlier identification of
high-risk patients should allow for the improved ability to slow
progressive decline in kidney function before patients reach late
stages of CKD and need a kidney transplant or dialysis.
For further information, please contact:
Renalytix AI plc www.renalytixai.com
James McCullough, CEO Via Walbrook PR
Stifel (Nominated Adviser & Broker) Tel: 020 7710 7600
Alex Price / Nicholas Moore
N+1 Singer (Joint Broker) Tel: 020 7496 3000
Aubrey Powell / George Tzimas (Corporate
Finance)
Tom Salvesen (Corporate Broking)
Walbrook PR Limited Tel: 020 7933 8780 or renalytix@walbrookpr.com
Paul McManus / Lianne Cawthorne Mob: 07980 541 893 / 07584 391
303
About RenalytixAI
RenalytixAI is a developer of artificial intelligence-enabled
clinical in vitro diagnostic solutions for kidney disease, one of
the most common and costly chronic medical conditions globally.
RenalytixAI's products are being designed to make significant
improvements in kidney disease diagnosis, transplant management,
clinical care, patient stratification for drug clinical trials, and
drug target discovery. For more information , visit
www.renalytixai.com .
About Kidney Disease
Kidney disease is now recognized as a public health epidemic
affecting over 850 million people globally. The Centers for Disease
Control and Prevention (CDC) estimates that 15% of US adults, or 37
million people, currently have chronic kidney disease (CKD).
Further, the CDC reports that 9 out of 10 adults with CKD do not
know they have it and 1 out of 2 people with very low kidney
function who are not on dialysis do not know they have CKD*. Kidney
disease is referred to as a "silent killer" because it often has no
symptoms and can go undetected until a very advanced stage. Each
year kidney disease kills more people than breast and prostate
cancer. Every day, 13 patients in the United States die while
waiting for a kidney transplant.
*
https://www.cdc.gov/kidneydisease/publications-resources/2019-national-facts.html
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
NRAFMMFTMTJJBAM
(END) Dow Jones Newswires
July 01, 2020 02:00 ET (06:00 GMT)
Renalytix (LSE:RENX)
Historical Stock Chart
From Apr 2024 to May 2024
Renalytix (LSE:RENX)
Historical Stock Chart
From May 2023 to May 2024